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Heme is an essential molecule expressed ubiquitously all through our tissues. Heme plays
major functions in cellular physiology and metabolism as the prosthetic group of diverse
proteins. Once released from cells and from hemeproteins free heme causes oxidative
damage and inﬂammation, thus acting as a prototypic damage-associated molecular
pattern. In this context, free heme is a critical component of the pathological process of
sterile and infectious hemolytic conditions including malaria, hemolytic anemias, ischemia-
reperfusion, and hemorrhage. The plasma scavenger proteins hemopexin and albumin
reduce heme toxicity and are responsible for transporting free heme to intracellular
compartments where it is catabolized by heme-oxygenase enzymes. Upon hemolysis or
severe cellular damage the serum capacity to scavenge heme may saturate and increase
free heme to sufﬁcient amounts to cause tissue damage in various organs.Themechanism
bywhich heme causes reactive oxygen generation, activation of cells of the innate immune
system and cell death are not fully understood. Although heme can directly promote lipid
peroxidation by its iron atom, heme can also induce reactive oxygen species generation
and production of inﬂammatory mediators through the activation of selective signaling
pathways. Heme activates innate immune cells such as macrophages and neutrophils
through activation of innate immune receptors. The importance of these events has been
demonstrated in infectious and non-infectious diseases models. In this review, we will
discuss the mechanisms behind heme-induced cytotoxicity and inﬂammation and the
consequences of these events on different tissues and diseases.
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HEME PHYSIOLOGY
Heme consists of a tetrapyrrole ring with an iron (Fe) atom
bound in the center, coordinated to the pyrrole rings (Kumar
and Bandyopadhyay, 2005). Heme is present in organisms of all
kingdoms being the prosthetic group of several proteins funda-
mental for the life of aerobic organisms (Wagener et al., 2003b).
In vertebrates, heme is ubiquitously expressed and its functions
are determined by the polypeptide interacting with it (Dawson,
1988). The capacity of the chelated Fe to undergo a reversible
change in the oxidation state renders heme a versatile biological
catalyst acting in oxidative reactions, electron transfer processes,
and delivering molecular oxygen (O2) to cells (Ryter and Tyrrel,
2000). Heme is presented in different forms, mostly in forms
a, b, and c. Heme a and c are important in the physiology of
electron transport and are found in cytochrome c oxidase (Tsuk-
ihara et al., 1995) and cytochrome c reductase (Xia et al., 1997;
Zhang et al., 1998), respectively. Heme b is the most common type
in mammals and is part of several proteins (Larsen et al., 2012)
including the gas carriers hemoglobin (Hb; Park et al., 2006) and
myoglobin (Evans and Brayer, 1988; Vojtechovsky et al., 1999),
hemeproteins related to heme release during hemolysis and tissue
damage. Importantly, heme b interaction with heme oxygenase
(HO; Lad et al., 2003), the enzyme responsible for heme intracellu-
lar catabolism, and hemopexin (Hx; Paoli et al., 1999), a plasmatic
heme scavenger, is essential for the regulation of free heme avail-
ability and Fe recycling (Kovtunovych et al., 2010; Tolosano et al.,
2010).
Besides its physiological importance, heme has a potent oxida-
tive capacity oxidizing lipids (Tappel, 1953, 1955; Vincent et al.,
1988) and proteins (Aft and Mueller, 1984; Vincent, 1989), and
damaging DNA (Aft and Mueller, 1983). Thus, heme can be
a dangerous molecule once released from hemeproteins. Some
diseases are characterized by high amounts of hemeproteins
out from their physiological environments. The consequences
of heme toxicity can be appreciated in hemolytic diseases such
as β-thalassemia, sickle-cell disease (SCD), ischemia-reperfusion
(IR), and malaria (Katori et al., 2002; Pamplona et al., 2007;Vinchi
et al., 2013). Extracellular and intracellular proteins have essen-
tial functions controlling free heme availability, guarding tissues
from its deleterious effects. Through evolution mammals acquired
several protective mechanisms against heme toxicity. Under phys-
iologic conditions or mild to moderate hemolysis, haptoglobin
(Hp) binds Hb (Melamed-Frank et al., 2001). Because of its large
molecular size, this complex is maintained in the intravascular
space, preventing the association of otherwise free Hb with nitric
oxide (NO; Reiter et al., 2002) and inhibiting the release of free
heme (Melamed-Frank et al., 2001). The complex Hp:Hb binds
to CD163 (Kristiansen et al., 2001), present in macrophages and
hepatocytes (Philippidis et al., 2004; Quaye, 2008), whichmediates
the endocytosis of Hb–Hp complexes for degradation. However,
during hemolytic diseases high amounts of Hb are released in the
intravascular environment, saturating the Hp molecules and thus
accumulating free Hb (Muller-Eberhard, 1970). In the presence of
reactive oxygen species (ROS), Hb is oxidized to methemoglobin
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(MetHb; Balla et al., 1993), characterized by the change in the
oxidative state of the Fe present in the heme molecule from ferrous
(Fe+2) to ferric (Fe+3). MetHb is unstable and rapidly releases free
heme (Balla et al., 1993). In this context, Hx scavenges free heme,
binding it with very high afﬁnity (Paoli et al., 1999). Hx inhibits
the oxidative property of heme (Eskew et al., 1999) and medi-
ates heme transportation to intracellular compartments through
the macrophage receptor CD91 (Hvidberg et al., 2005), a critical
step on heme catabolism. Once inside the cells, heme is catabo-
lized byHOenzymes, generating equimolar amounts of biliverdin,
carbon monoxide (CO), and Fe (Tenhunen et al., 1968). Dif-
ferently from biliverdin and CO, which have anti-inﬂammatory
effects (Otterbein et al., 2000; Baranano et al., 2002), free Fe is
highly oxidative and can promote free radicals generation through
the Fenton reaction, which catalyzes hydroxyl radicals from the
reaction of Fe with H2O2 (Fenton, 1894). These radicals initi-
ate lipid-chain peroxidation by obtaining electrons from other
molecules, including unsaturated fatty acid (RH), generating an
alkyl radical (R•; Ryter and Tyrrel, 2000). Thus, labile Fe can
induce cytotoxic effects (Gozzelino et al., 2012). In this context,
the HO function is complemented by ferritin, a ubiquitous intra-
cellular protein complex that stores Fe in a soluble and non-toxic
form (Eisenstein et al., 1991). Ferritin is composed of a heavy and
a light chain which cooperates in the overall uptake and store
of Fe in a non-toxic form protecting cells from hydroxyl radi-
cals generated through the Fenton reaction (Arosio et al., 2009).
While the ferritin heavy chain (FtH) presents a ferroxidase activity
that converts the Fe from Fe+2 into Fe+3 (Broxmeyer et al., 1991),
the ferritin light chain (FtL) is essential to promote Fe nucleation
(Levi et al., 1992). Cells deﬁcient on FtH are more susceptible
to oxidative damage, while increased amounts of FtH protects
cells from death induced by challenges such as Fe, tumor necro-
sis factor (TNF), heme, heme plus TNF, or oxidized low-density
lipoprotein (LDL; Juckett et al., 1995; Pham et al., 2004; Gozzelino
et al., 2012). All these effects require the ferroxidase activity of
FtH.
Not only vertebrates need to manage high amounts of free
heme. Hematophagous arthropods, upon digestion of Hb in the
mid-gut, are exposed to enormous quantities of free heme and
ROS.Different blood-sucking species have developed independent
adaptations to deal with heme toxicity, including heme aggrega-
tion (Oliveira et al., 1999), heme degradation (Paiva-Silva et al.,
2006; Pereira et al., 2007), expression of heme-binding proteins
(Oliveira et al., 1995), and induction of antioxidant systems (Paes
et al., 2001; Oliveira et al., 2011).
DIRECT CYTOTOXIC EFFECTS OF HEME
The cytotoxicity of heme was initially associated with a direct
effect due to its structural properties, speciﬁcally the capacity
of the hydrophobic porphyrin ring to intercalate lipid layers
and the presence of the atom of Fe, considered essential for
heme-induced ROS generation. Heme can destabilize biologi-
cal membranes increasing its permeability and the chance of
lysis (Schmitt et al., 1993), as it happens with erythrocytes (Chiu
and Lubin, 1989). This effect relies in the amphipathic prop-
erties of the porphyrin ring rendering heme the tendency to
allocate in non-polar niches including lipoproteins and lipid
membranes where it might establish dangerous contacts with
lipids, important targets of peroxidation by ROS (Rose et al.,
1985; Light and Olson, 1990a,b). Once intercalated into cellu-
lar plasma membranes heme ampliﬁes cellular susceptibility to
oxidative-mediated injury by oxidants such as H2O2 or those
derived from activated inﬂammatory cells (Balla et al., 1991a,b,
1993). Because heme has an atom of Fe in its structure and
can sensitize cellular membranes to H2O2, it was proposed that
heme-induced cytotoxicity could be derived from free radicals
generated through the Fenton reaction (Vincent, 1989; Chiu et al.,
1996). However, conﬂicting data makes uncertain that heme can
directly catalyze this reaction. Studies using electron paramagnetic
resonance (EPR) spin-trapping techniques, in cell free condi-
tions, suggested that neither MetHb (Mao et al., 1994), nor free
heme (Van der Zee et al., 1996), can catalyze the Fenton reac-
tion generating hydroxyl radicals. Furthermore, heme induces
ROS generation dependent on enzymatic reactions. In fact, it
was demonstrated that heme triggers ROS production by the
NADPH oxidase enzyme (Graça-Souza et al., 2002; Arruda et al.,
2004; Moraes et al., 2012; Barcellos-de-Souza et al., 2013) and
by mitochondria (unpublished), through activation of speciﬁc
signaling pathways (Graça-Souza et al., 2002; Porto et al., 2007;
Fernandez et al., 2010; Fortes et al., 2012). Alternatively, heme-
induced formation of radical species relies on the conversion of
low-reactive organic hydroperoxides (ROOH) into highly reactive
alkoxyl (RO•) and peroxyl (ROO•) radicals (Tappel, 1953, 1955;
Van der Zee et al., 1996). These radicals may initiate further lipid
peroxidation forming alkyl radicals that in the presence of O2
form more peroxyl radicals leading to a facile propagation of free
radical reactions. Ultimately, alkyl radicals are rearranged to form
toxic conjugated diens and stimulate the autocatalytic lipid per-
oxidation cascades (Ryter and Tyrrel, 2000) which could mediate
heme-induced toxicity. Together, these data suggest that the cyto-
toxic heme effects can be mediated by ROS from different sources
generated both through non-enzymatic and enzymatic reactions.
This leads to at least four possible mechanisms of heme-induced
ROS: (1) heme might directly promote ROS generation by the Fe
present in its structure through the Fenton reaction, (2) Fe might
be released from heme to exert its oxidative effects, (3) heme can
activate signaling pathways to induce ROS generation enzymati-
cally, or (4) heme can convert organic hydroperoxides into free
radicals.
INFLAMMATORY EFFECTS OF HEME
Heme activates innate immune cells and non-hematopoietic cells
promoting inﬂammation. Heme injection inmice leads to vascular
permeability, leukocyte migration from the intravascular environ-
ment to tissues and increase of acute-phase proteins (Lyoumi et al.,
1999; Wagener et al., 2001b), hallmarks of acute inﬂammation.
Heme activates endothelial cells inducing the expression of the
adhesion molecules ICAM-1 (intercellular adhesion molecule 1),
VCAM-1 (vascular cell adhesion molecule 1), E-selectin, P-
selectin, and von Willebrand factor (VWF; Wagener et al., 1997;
Belcher et al., 2014) and causes neutrophil migration (Graça-
Souza et al., 2002; Porto et al., 2007). The adhesion molecules
enable neutrophils to attachﬁrmly to the endotheliumandmigrate
to tissues parenchyma. Thus, leukocytes must be activated and
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express adhesion molecules complementary to those expressed by
the endothelium. A seminal study demonstrated that the abil-
ity of heme to activate neutrophils depend on protein kinase C
(PKC) activation and ROS generation, inducing the expression of
adhesion molecules and modifying actin cytoskeleton dynamics,
necessary features for neutrophils migration (Graça-Souza et al.,
2002). In fact, heme can induce neutrophil migration by act-
ing as a chemotactic molecule (Porto et al., 2007) or by inducing
the production of leukotriene B4 (LTB4) by macrophages (Mon-
teiro et al., 2011). Heme-induced neutrophils activation leads to
extracellular traps (NETs) release through a mechanism depen-
dent on ROS generation (Chen et al., 2014). Moreover, heme
induces the production of the chemokine interleukin (IL)-8
by endothelial cells (Natarajan et al., 2007) and by neutrophils
(Graça-Souza et al., 2002). Although neutrophils have impor-
tant functions controlling infection, these cells can promote
vascular and tissue injury by generating ROS, secreting pro-
teases, and releasing extracellular chromatin (NETs; reviewed in
Mócsai, 2013). Consequently, the prolonged activity of these cells
is detrimental for tissue homeostasis. In this context, heme inhibits
neutrophils apoptosis, increasing their longevity, and possibly
enhancing harmful stimuli from these cells (Arruda et al., 2004,
2006).
Macrophages stimulate inﬂammatory responses by secreting
cytokines, chemokines, and lipid mediators. TNF, IL-6, and IL-1β
are pleiotropic cytokines that regulate cell death, increase vas-
cular endothelial permeability, recruit immune cells to inﬂamed
tissues and induce the production of acute-phase proteins. Part
of these effects is mediated by the activation of ﬁbroblasts and
endothelial cells, especially by TNF and IL-1β. Moreover, IL-1β
and TNF modiﬁes the hypothalamus threshold of the body tem-
perature causing fever. KC (keratinocyte-derived chemokine) is
a chemokine that attracts neutrophils to sites of inﬂammation
and LTB4 is a lipid mediator that functions as a chemoat-
tractant molecule and also activates leukocytes. Heme activates
macrophages inducing the production of TNF, KC (Figueiredo
et al., 2007), IL-1β (unpublished), and LTB4 (Monteiro et al.,
2011). Although KC and IL-1β functions were not investigated
during heme-induced inﬂammatory effects, TNF and LTB4 were
described as essential inﬂammatory mediators during inﬂamma-
tory events induced by heme. As described before, LTB4 has an
important function regulating heme-induced neutrophils migra-
tion (Monteiro et al., 2011). On the other hand, TNF secretion
induced by heme is essential for the activation of the programed
necrotic cell death pathway, which is denominated necroptosis
(Fortes et al., 2012).
Hemoglobin is used as a nutrient byPlasmodium, the protozoan
parasite that causes malaria, during its replication stage inside ery-
throcytes in the course of the infection in mammals (Francis et al.,
1997). Hb digestion generates high amounts of free heme which
is detoxiﬁed by its polymerization into a crystal structure named
hemozoin (Hz; Slater et al., 1991; Slater, 1992; Pandey and Tek-
wani, 1996). Once released from ruptured erythrocytes, Hz can be
phagocytized and accumulated inside macrophages altering their
functions. Similarly to heme, Hz also induces the production of
several inﬂammatorymediators bymacrophages such as cytokines
and chemokines, and induces leukocytes migration (reviewed
by Olivier et al., 2014). In nature, Hz produced by Plasmodium
spp. carries DNA from the parasite. Because DNA is immuno-
genic and can activate innate immune receptors (Yanai et al., 2009;
Coban et al., 2010), the exact role of pure Hz in the activa-
tion of innate immunity is not completely understood (discussed
later).
Together, these inﬂammatory responses triggeredbyheme indi-
cate that heme is a damage-associated molecular pattern (DAMP),
a group of endogenous molecules derived from damaged cells and
extracellularmatrix degradation capable of promoting and exacer-
bating immune responses. These concepts challenged the idea that
the cytotoxic and inﬂammatory effects of heme were exclusively
mediated by the oxidative capability of the Fe associated with the
amphipathic property of the porphyrin ring. Moreover, albeit the
controversy aboutHz immunogenicity,Hz composed of heme and
Plasmodium DNA can be deﬁned as a pathogen-associated molec-
ular pattern (PAMP) in the course of malaria infection, promoting
inﬂammation and contributing to pathogenesis.
HO-1 PROTECTION AGAINST HEME
Plasma scavengers of heme and/or Hb once saturated allow
heme to exert its inﬂammatory properties. In fact, hemolysis
or heme injection in Hx−/− mice cause increased inﬂamma-
tion and severe renal damage compared to wild type (WT)
mice (Tolosano et al., 1999; Vinchi et al., 2008). Mice lacking
HO-1 (Hmox1−/−) are highly susceptible to pathologic condi-
tions associated with increased serum heme concentration. For
instance, Hmox−/− mice develops acute renal failure and marked
mortality when submitted to rhabdomyolysis, a pathological con-
dition that increases serum myoglobin which can be oxidized
and release heme (Nath et al., 2000). Furthermore, Hmox1−/−
mice are susceptible to liver IR which is characterized by tis-
sue damage in sites that are reperfused after ischemia injury
and hemolysis (Devey et al., 2009). Thus, HO-1 regulation by
heme is an essential feedback mechanism that maintains tissue
homeostasis through anti-inﬂammatory and anti-oxidant activ-
ities in pathologic situations associated to heme (reviewed by
Gozzelino et al., 2010). SCD and β-thalassemia are genetic dis-
eases associated to erythrocytes that are prone to lysis due to
defective Hb production (Heinle and Read, 1948; Pauling et al.,
1949; Ingram, 1957; discussed later). Asymptomatic humans with
sickle-cell trait are protected against malaria disease. Interest-
ingly, this fact was suggested to be dependent on heme-induced
HO-1 expression. Transgenic sickle-cell hemizygous mice are
protected against malaria disease (Ferreira et al., 2011). Besides
the fact that these mice do not develop anemia, hemolysis is
evidenced by a modest serum heme increase which is sufﬁ-
cient to increase HO-1 expression and CO production (Ferreira
et al., 2011). CO inhibits Hb oxidation and subsequently heme
release, thus blocking heme accumulation in serum and prevent-
ing heme from exerting its inﬂammatory effects in the course
of malaria disease (Ferreira et al., 2011). This case demonstrates
the importance of the feedback production of HO-1 induced by
heme to maintain tissue homeostasis. Moreover, heme accumu-
lates in wounded areas and promotes inﬂammation through the
expression of adhesion molecules and the recruitment of leuko-
cytes (Wagener et al., 2003a). During the resolution phase of
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inﬂammation HO-1 expression in leukocytes reduces adhesion
molecules expression and leukocytes migration, thus contributing
to wound healing (Wagener et al., 2003a). Although heme is a pro-
inﬂammatory molecule, the feedback activity of HO-1 inhibits
exacerbated inﬂammation and maintains homeostasis. However,
the efﬁciency of HO-1 to counteract heme depends on the health
state of the individual. Heme administration in mice without a
genetic or pathologic condition that cause susceptibility to heme
might have a therapeutic effect dependent on the activity of HO-1.
In fact, heme-induced HO-1 expression prevents injury induced
by indomethacin in the intestine (Yoriki et al., 2013), unilateral
ureteral obstruction in the kidney (Correa-Costa et al., 2010),
nutricional steatohepatitis (Nan et al., 2010), and IR in the liver
(Xue et al., 2007).
INNATE IMMUNE RECEPTORS ACTIVATED BY HEME
The immune system is characterized by the exquisite recognition
of exogenous and endogenous molecules, and by its central role in
tissue homeostasis as well as contributing to the pathogenesis of
several diseases. The physiological consequence of an infection is
the activationof an immune response essential to pathogen control
or elimination (Medzhitov, 2008). Similarly, sterile tissue dam-
age triggers inﬂammatory responses fundamental to tissue repair
(Nathan and Ding, 2010). For years the mechanism of innate cell
activation and function was considered non-speciﬁc, in opposi-
tion to the ability of B and T lymphocytes to recognize antigens by
clonal receptors. The speciﬁc recognition of molecules from infec-
tious agents and from endogenous origin by innate immune cells
is performed by evolutionary conserved membrane and cytoso-
lic receptors also known as pattern recognition receptors (PRRs;
reviewed in Takeuchi and Akira, 2010). The presence and func-
tion of these receptors on mammals were originally proposed by
Janeway (1989) and ﬁrst conﬁrmed by his group (Medzhitov et al.,
1997). PRRs are germline-encoded and represent an essential arm
of innate immune cells to sense invading microbes through con-
served PAMPs and to detect endogenous stress signals through
DAMPs. Several families of innate immune receptors have been
described in recent years.
HEME TRANSPORTERS
For decades it has been appreciated that the transport of nutri-
tional heme across cellular membranes of intestinal epithelial
cells is an active and regulated process, more efﬁcient than free
Fe transport, requiring energy, and a selective transporter. The
molecular nature of mammalian heme transporters remained
elusive for many years, in part due to the lack of molecular
and genetic tools and also as a consequence of a number of
membrane proteins able to bind and transport heme at low
afﬁnity. In fact, several transporters of heme and other por-
phyrins have been described in recent years, although the in
vivo importance of some of these molecules on heme trafﬁck-
ing is still object of debate. The cytoplasmic heme importer,
named heme carrier protein 1 (HCP1), is expressed in the cyto-
plasmic membrane of duodenal epithelial cells and is believed
to participate on dietary heme absorption (Shayeghi et al., 2005;
Latunde-Dada et al., 2006). It was also demonstrated the crit-
ical in vivo importance of this putative heme transporter as
a mediator of extracellular folate import by intestinal epithe-
lial cells (Qiu et al., 2006). Similarly, the ATP-binding cassette,
Abcg2, involved on heme export is also associated with mul-
tidrug resistance (Krishnamurthy et al., 2004; Krishnamurthy
and Schuetz, 2006). A second exporter of heme is the feline
leukemia virus subgroup C receptor 1 (FLVCR1), in this case
the lack of the transporter in mice affects erythroid differentia-
tion and cell survival (Quigley et al., 2004; Keel et al., 2008). A
mitochondrial isoform of FLVCR1 named FLVCR1b was recently
demonstrated to export heme from the mitochondria to the
cytosol (Chiabrando et al., 2012). The heme transporter ATP-
binding cassette, Abcb6, controls the translocation of protopor-
phyrin between the cytosol and themitochondria (Krishnamurthy
et al., 2006). The heme-responsive gene-1 (HRG1) participates in
the translocation of heme between the cytosol and endosomal
compartments (Rajagopal et al., 2008).
An interesting study demonstrated that heme binds with high
afﬁnity to a heme-binding motif present at the intracellular
domain of Slo1 channels, and inhibits transmembrane K cur-
rents by decreasing the frequency of channel opening (Tang et al.,
2003). This was the ﬁrst demonstration of an acute signaling effect
of heme dependent on a speciﬁc transmembrane protein. Heme
interactions with these membrane proteins led us to hypothesize
that heme activates cells of the innate immune system through
binding to an innate immune receptor.
HEME IS AN AGONIST OF TOLL-LIKE RECEPTOR 4
Using mouse strains deﬁcient in different adaptors and innate
immune receptors, we observed that heme-induced TNF produc-
tion was dependent on MyD88 and Toll-like receptor 4 (TLR4;
Figueiredo et al., 2007). TLRs are receptors present in mice and
humans, which are distributed among the cellular membrane
and intracellular compartments, as endosomes and lysosomes
(Takeuchi and Akira, 2010). Each TLR recognize one or more
PAMPs derived from different microbes such as bacteria, fungi,
parasites, and virus (Takeuchi and Akira, 2010). Besides microbial
agonists, TLRs triggers inﬂammatory responses to endogenous
inﬂammatory molecules. DAMPs that activate TLRs include the
high-mobility group box 1 (HMGB1) nuclear protein, myeloid-
related proteins (Mrp8/14), amyloid β, oxidized LDL (oxLDL),
DNA, and RNA in the form of immune complexes, mitochon-
drial DNA (Oka et al., 2012) and extracellular matrix components
such as tenascin-C, ﬁbronectin, and hyaluronan (reviewed by Yu
et al., 2010). Other DAMPs such as ATP, formyl peptides, uric
acid crystals, and cholesterol crystals activate other innate immune
receptors (Mariathasan et al., 2006; Martinon et al., 2006; Duewell
et al., 2010; discussed later).
A critical step in characterizing an endogenous molecule as an
agonist of an innate immune receptor is the necessity to exclude
the presence of any microbial contaminant. In fact, in the case
of heat shock proteins (HSPs), the effect on TNF secretion was
later attributed to endotoxin contamination in the protein prepa-
rations (Gao and Tsan, 2003). Several strategies were used to
exclude that the TLR4-induced activation by heme was due to
contaminant (Figueiredo et al., 2007). Highly puriﬁed heme free
of endotoxin contamination was used, as well as polymyxin B,
anti-TLR4/MD2, and lipid A antagonist, all of which inhibited
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the effects of LPS but did not interfere with the induction of
TNF by heme. Similarly, protoporphyrin IX (PPIX), an antag-
onist of heme, did not inhibit the activity of LPS on TNF
secretion (Figueiredo et al., 2007). The TLR4 engagement by LPS
triggers two distinct pathways by the recruitment of the adap-
tor molecules MyD88 (Muzio et al., 1997; Wesche et al., 1997)
and TRIF [TIR (Toll–IL-1 receptor)-domain-containing adapter-
inducing interferon (IFN)-β; Hoebe et al., 2003; Yamamoto et al.,
2003]. The MyD88-dependent pathway leads to the activation of
mitogen-activated protein kinases (MAPKs) and NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells) transcrip-
tion factors inducing the expression of inﬂammatory cytokines
such as TNF, IL-6, IL-1β, and KC (Takeuchi and Akira, 2010).
The TRIF-dependent pathway activates the IRF3 (IFN regulatory
transcription factor-3), which induce the expression of type I
IFN, and late-phase NF-κB (Takeuchi and Akira, 2010). Heme
seems to activate only the MyD88-dependent pathway and is
ineffective to induce several cytokines or the expression of co-
stimulatory molecules typical of TLR4 activation by LPS. It can
induce MAPK activation and the expression of TNF and KC,
but not of IFNβ or the IFN-dependent gene IP-10 (Figueiredo
et al., 2007; Figure 1). Even the transcription of certain MyD88-
dependent genes is not induced by heme when compared to LPS.
In fact, different TLR4 ligands trigger signaling pathways differ-
ently. While, monophosphoryl lipid A, an analog of the TLR4
agonist tetra-acylated lipid A, induces a biased response to the
TRIF pathway (Mata-Haro et al., 2007), the vesicular stomatitis
virus glycoprotein G induces a biased response to the TRAM path-
way to speciﬁcally induce IRF7 activation (Georgel et al., 2007).
Moreover, human embryonic kidney (HEK) cells transfected with
human TLR4 secretes IL-8 upon stimulation with heme (Piazza
et al., 2011). In this case, the experiments were performed in the
absence of CD-14 and MD-2 transfection.
The differences in signaling pathways activated by different
agonists of the TLR4 might be due to (1) a different binding
site on the TLR4, compared to LPS, or perhaps (2) the involve-
ment of different co-receptors. (1) Molecular determinants of
heme structure for TLR4 activation were determined (Figueiredo
et al., 2007). Heme (Fe-PPIX) analogs, porphyrin rings without
Fe (PPIX) or with metal substitutions (Pd-PPIX and Sn-PPIX), do
not induce TNF production. Fe-mesoporphyrin IX, a heme analog
with two ethyl groups substituting its vinyl groups, also is unable
to activate TLR4. These data suggests that coordinated Fe and the
vinyl groups are necessary for heme effect on TNF production.
PPIX functions as an antagonist for TNF production induced by
heme but not by LPS (Figueiredo et al., 2007). Conversely, LPS
antagonists do not inhibit TNF production induced by heme.
Interestingly, the sequence comparison of TLR4 and globins from
different species suggests the presence of conserved heme-binding
sequences in TLR4 (unpublished). These conserved sequences
FIGURE 1 | Heme activates TLR4 in macrophages. The TLR4 activates
two distinct pathways: MyD88 and TRIF. In macrophages, heme
induces a biased MyD88 activation and the secretion of the
pro-inﬂammatory cytokines TNF and KC. TLR4 activation leads to
MAPKs and NFκB activation, which are necessary to TNF secretion.
Heme induces ROS generation independently of TLR4. However, ROS
is necessary to induce TNF secretion and MAPK activation. Thus, TLR4
activation and ROS generation seem to be complementary and both
are required for MAPKs and IκB degradation. It will be important to
determinate the source of ROS and the mechanisms triggering
heme-induced ROS generation. The mitochondria and the NADPH
oxidase complexes seem to be involved. mROS scavenger
(Mito-TEMPO) and NADPH oxidases inhibitors (apocynin and DPI) block
TNF production induced by heme.
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present a histidine which is essential for heme to bind globins.
It is tempting to speculate that this histidine is essential for heme
induced TLR4 activation. In fact, this same conserved histidine,
together with two others non-conserved histidines, was shown to
be important for the TLR4 activation induced by nickel in humans
cells (Schmidt et al., 2010). The lack of these non-conserved his-
tidines in the murine TLR4 disables the nickel capacity to activate
this receptor. Moreover, this conserved histidine is important
to Nickel, but not to LPS, to activate the TLR4. (2) Depending
on the TLR4 activator, different co-receptors will be involved.
LPS depends on MD2 and CD14 to activate TLR4 (Park et al.,
2009). Amyloid β and oxLDL induce the assembly of a CD36–
TLR4–TLR6 complex (Stewart et al., 2010), while hyaluronan is
recognized by a complex formed by TLR4, MD2, and CD44 (Tay-
lor et al., 2007). Heme depends on CD14 but not MD2 to activate
TLR4 and induce TNF (Figueiredo et al., 2007; Piazza et al., 2011).
The crystal structure formed by heme polymerization, Hz,
has pro-inﬂammatory properties dependent on TLR9 activation.
However, it is uncertain whether pure Hz can directly activate
TLR9. Because Hz isolated from P. falciparum cellular extract
may contain DNA, this might be the TLR9 activator. In fact, it
was shown that DNase treatment of Plasmodium Hz abolishes
cytokine production by dendritic cells (DCs; Parroche et al., 2007).
However, there is evidence that synthetic Hz, which is free of
DNA, induces TLR9-dependent responses in DCs (Coban et al.,
2005). Moreover, synthetic Hz induces conformational changes
in recombinant TLR9, similar to those induced by CpG DNA,
a well characterized TLR9 agonist (Coban et al., 2010). Interest-
ingly, heme was able to induce similar conformational changes
in the recombinant TLR9 (Coban et al., 2010). However, we
demonstrated that TLR9 was not involved in heme-induced TNF
production because WT and Tlr9−/− macrophages produce simi-
lar amounts of TNF when stimulated with heme (Figueiredo et al.,
2007). Moreover, this demonstration suggests that mitochondrial
DNA, a TLR9 activator (Oka et al., 2012), is not involved in the
production of TNF by heme.
G PROTEIN-COUPLED RECEPTORS
As mentioned before, heme induces LTB4 production by
macrophages to stimulate neutrophil migration in vivo (Mon-
teiro et al., 2011). Surprisingly, heme can also induce neutrophil
migration in vitro thus indicating that heme acts as a chemo-
tactic molecule (Graça-Souza et al., 2002; Porto et al., 2007).
Chemokines and chemotactic molecules can induce neutrophil
migration through G protein-coupled receptors (GPCR) which
are sensitive to pertussis toxin (reviewed in Rot and von Andrian,
2004). Pertussis toxin inhibits heme-induced ROS generation
and neutrophil migration, thus suggesting the involvement of
a GPCR (Porto et al., 2007). Pharmacological inhibition of sev-
eral pathways activated by GPCR [PI3K, PKC, phospholipase
C (PLC)β, Rho, p38] demonstrated that ROS generation and
neutrophil migration depends on the activation of signaling
pathways characteristic of chemotactic receptors (Porto et al.,
2007). Interestingly, PI3K and MAPK activation delays neu-
trophil apoptosis through a NADPH oxidase-dependent mech-
anism (Graça-Souza et al., 2002). This indicates that similar
pathways might be involved in ROS generation, survival, and
migratory mechanisms triggered by heme in neutrophils. Fur-
thermore, although several heme analogs were able to induce
neutrophil migration, mesoporphyrins, molecules lacking the
vinyl groups in their rings, were not chemotactic for neu-
trophils and selectively inhibited the migration induced by heme
(Porto et al., 2007). We believe that mesoporphyrins functions
as antagonist molecules blocking the activation of an extracellu-
lar receptor. Cytochrome c has a conserved sequence responsible
for its interaction with heme. This same sequence is present
in the Slo1 channel and was proved to be essential for its
binding to heme (Tang et al., 2003). Interestingly, we found
this conserved sequence in two chemotactic receptors expressed
in neutrophils. Together, these results raises the possibility
that heme activates neutrophils through the activation of a
GPCR.
MECHANISMS INVOLVED IN HEME-INDUCED CELL DEATH
AND INFLAMMATION
CYTOTOXIC EFFECTS CONTROLLED BY SPECIFIC SIGNALING
PATHWAYS
Because of its lipid intercalating ability, heme was assumed to
induce its cytotoxic and inﬂammatory effects mediated by its
pro-oxidant and amphipathic properties. However, new possi-
bilities emerged because of the new characterized mechanisms
of inﬂammatory responses induced by heme. Heme activates
TLR4 to induce cytokine production and necrotic cell death
(Figueiredo et al., 2007; Fortes et al., 2012; Figure 2). Heme-
induced necrosis depends on TNF produced by TLR4 activation,
because Tlr4−/− and Tnfr−/− macrophages are resistant to the
cytotoxic effects of heme (Fortes et al., 2012). However, heme
sensitizes Tlr4−/− macrophages to TNF-induced cell death, indi-
cating that TLR4 is essential to heme-induced TNF production,
but not directly required for the cell death induced by heme.
The necrotic cell death induced by heme was dependent on
ROS generation, since antioxidants prevented it (Fortes et al.,
2012). Moreover, Rip1−/− and Rip3−/− cells were resistant to
heme-induced necrotic cell death (Fortes et al., 2012), charac-
terizing the type of programed cell death as necroptosis (Cho
et al., 2009; He et al., 2009; Zhang et al., 2009). Interestingly,
ROS induction is essential but not sufﬁcient to cause cell death.
In fact, TLR4 and TNFR deletions do not change the capac-
ity of heme to induce ROS generation (Figueiredo et al., 2007).
Therefore, it is clear that heme triggers ROS-induced sensitiza-
tion of macrophages to TNFR-mediated cell death through RIP1
and RIP3 activation to promote necroptosis (Figure 2). More-
over, inhibition of Jun N-terminal kinase (JNK) also decreases
heme-induced ROS and necroptosis (Fortes et al., 2012; Figure 2).
Heme-inducednecroptosis is reversedbydeferoxamine, a Fe chela-
tor. Fe can mediate non-enzymatic ROS generation by the Fenton
reaction. However, since deferoxamine binds to heme (Baysal
et al., 1990; Lu et al., 2012), we cannot exclude the possibility
that its inhibitory effect is directly related to heme and not to
free Fe. In fact, the protective effect of pharmacologic inhibition
of NADPH oxidase and mitochondrial ROS (mROS) on heme-
inducedTNFandmacrophage necroptosis suggests that enzymatic
ROS production is essential for the cytotoxic effects of heme
(unpublished).
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FIGURE 2 | Heme induces RIP1/RIP3-dependent programed cell death.
Heme triggers two distinct but integrated pathways to promote necroptosis.
Heme induces ROS generation independently of TLR4. ROS sensitizes
macrophages to TNFR-induced cell death. Heme-inducedTLR4 activation
leads to MAPKs activation andTNF production.While JNK increases ROS
generation, TNF induces RIP1–RIP3 necrosome which triggers necroptosis.
The mitochondria and the NADPH oxidase complexes seem to be involved.
mROS scavenger (Mito-TEMPO) and NADPH oxidases inhibitors (apocynin
and DPI) block heme-induced necroptosis. Necroptosis only develops when
caspases are inhibited. However, it is not known if heme requires caspase
inhibition to induce necroptosis. Moreover, HO-1 has a protective effect
during heme-induced necroptosis.
Heme also induces programed cell death in non-hematopoietic
cells. Stimulation of astrocytes with heme, as a model of hemor-
rhagic injury, causes cell death with characteristics of programed
necrosis including the loss of plasma membrane integrity, rever-
sion by necrostatin-1, a selective inhibitor of RIP1, and by
antioxidants (Laird et al., 2008). Extracellular-signal-regulated
kinase (ERK) activation is also involved in astrocyte cell death
induced by heme (Regan et al., 2001). Interestingly, heme-induced
ERK activation in these cells is ROS-independent (Regan et al.,
2001) indicating the involvement of a distinct pathway that might
involve TLR4 signaling. In fact, TLR4 is involved in intracerebral
hemorrhage (ICH) induced by heme (Lin et al., 2012). Microglia
cells, another cell type present in the central nervous system,
undergoes cell death through heme-induced activation of JNK
and p38 (Cai et al., 2011). Moreover, heme induces apoptosis in
human brain vascular endothelial cells (HBVEC) by STAT3 (signal
transducer and activator of transcription 3)-dependent activation
of matrix metallopeptidase 3 (MMP3; Liu et al., 2013). Heme
also sensitizes other non-hematopoietic cells to TNF-induced cell
death (Seixas et al., 2009; Larsen et al., 2010; Sukumari-Ramesh
et al., 2010; Gozzelino et al., 2012). This cell death has mor-
phological and biochemical characteristics of apoptosis including
caspase activation, membrane blebbing, nuclear shrinking, and
fragmentation, as well as chromatin condensation and forma-
tion of apoptotic bodies (Seixas et al., 2009). Treatment with
antioxidants, increased expression of HO-1 or Hx also revert the
heme/TNF-induced cell death in hepatocytes (Seixas et al., 2009;
Gozzelino et al., 2010, 2012; Larsen et al., 2010; Gozzelino and
Soares, 2011).
Heme induces HO-1 that in turn protects cells from death (Vile
et al., 1994; Poss and Tonegawa, 1997a; Ferris et al., 1999; Brouard
et al., 2002; Arruda et al., 2004; Seixas et al., 2009; Gozzelino et al.,
2010; Kovtunovych et al., 2010; Larsen et al., 2010). The ability of
HO-1 to promote cytoprotection has been attributed to its role
controlling heme amounts as well as Fe homeostasis and oxidative
stress (Gozzelino et al., 2010). Mice lacking HO-1 (Hmox1−/−)
has Fe overload, increase cell death and widespread inﬂamma-
tion (Poss and Tonegawa, 1997a,b; Kovtunovych et al., 2010). In
vitro embryonic ﬁbroblasts from Hmox1−/− mice are more sen-
sitive to heme or H2O2 and present increase oxidative stress (Poss
and Tonegawa, 1997a). Moreover, Hmox1−/− mice have reduced
macrophage numbers in the spleen and liver due to cell death
(Kovtunovych et al., 2010). This increased macrophage cell death
was conﬁrmed in vitro upon erythrophagocytosis, further suggest-
ing that the in vivo exposure to heme is the cause of the increased
macrophage death observed inHmox1−/− mice. This result is cor-
roborated by the increased necroptosis observed in Hmox1−/−
macrophages exposed to heme compared to WT (Fortes et al.,
2012). Treatment with antioxidants fully blocked heme-induced
cell death of Hmox1−/− macrophages.
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Importantly, increased expression of FtH also protects differ-
ent cell types from the cytotoxic effects of heme, TNF or heme
and TNF (Balla et al., 1992; Berberat et al., 2003; Cozzi et al., 2003;
Gozzelino et al., 2012). These results suggest that Fe derived from
heme catabolism participates in the heme-induced sensitization
to cell death. The mechanism depends on the sustained activation
of JNK induced by Fe-derived ROS. The increased JNK activa-
tion inhibits FtH expression, increasing the amount of labile Fe
and consequently the amounts of ROS. The antioxidant property
of FtH blocks TNF-induced JNK activation, reducing cell death
(Pham et al., 2004; Kamata et al., 2005; Gozzelino et al., 2012).
Thus, it seems that JNK activation is a common trigger of heme-
induced cell death in a variety of cells (macrophages, hepatocytes,
andmicroglia; Figure 2). Thus heme induces programed cell death
in different types of cells by the regulation of speciﬁc signaling
pathways.
THE SPLEEN TYROSINE KINASE PATHWAY OF INFLAMMATION
The cytotoxic effect of heme has important impact in differ-
ent pathological conditions. This is in part due to the loss of
essential tissue functions and in part due to the release of cel-
lular contents with inﬂammatory activities. High amounts of free
heme are found in infectious diseases, such as malaria and sepsis
(Pamplona et al., 2007; Larsen et al., 2010), suggesting that heme
can amplify inﬂammatory responses during infection. In fact, it
was demonstrated that dying hepatocytes release HMGB1 upon
heme and TNF challenge, which in turn increases the systemic
inﬂammatory response (Larsen et al., 2010). Another mechanism
involved in heme-induced inﬂammation during infectious condi-
tions is the ampliﬁcation of cytokine production induced by heme
with microbial molecules. Hb synergizes with LPS enhancing
the production of pro-inﬂammatory cytokines by macrophages
(Yang et al., 2002). The opposite effect of globin indicates that
heme moiety is the responsible for the potentiating effect of
Hb. A low dose of LPS on its own that causes an insigniﬁcant
cytokine secretion, together with heme results in substantial pro-
duction of cytokines, thus suggesting that this synergism may
be particularly important under conditions of low agonist con-
centrations, helping the control of infectious agents (Fernandez
et al., 2010). This ampliﬁcation response can also be deleterious
under higher concentrations of heme and microbial molecules.
In vivo, injection of heme and LPS induces a signiﬁcant increase
in the concentrations of TNF and IL-6 when compared to the
challenge with LPS alone (Fernandez et al., 2010). Moreover, the
co-injection of non-lethal doses of heme and LPS induces 100%
lethality.
Interestingly, although puriﬁed Hx inhibits the synergy
between heme and PAMPs, the synergy only occurs in the
presence of serum, a condition that protects the cells against
heme-inducedTLR4-dependentTNFproduction andnecroptosis.
Heme synergizes with ligands of TLR2, TLR3, TLR4, TLR9,NOD1
(nucleotide-binding oligomerization domain 1), and NOD2 to
increase TNF and IL-6 production by macrophages (Figure 3).
The synergy between heme and LPS, a TLR4 activator, is induced
by the enhanced activation of MAPKs (ERK,p38, JNK) andNF-κB
(Fernandez et al., 2010; Figure 3). The mechanism depends on
spleen tyrosine kinase (Syk) phosphorylation which regulates the
ROS production induced by heme (Figure 3). Heme-induced Syk
phosphorylation modulates ROS generation by activating PKC
and calcium signaling through PLCγ, two downstream molecules
regulated by Syk, which are involved in the synergy between
heme and LPS (Fernandez et al., 2010). In fact, Syk modulates
signaling pathways activated by TLRs cytokine production by
macrophages and DC (Brown et al., 2003; Gantner et al., 2003;
Turnbull et al., 2005). Syk is a signaling molecule activated by
receptors that signal through immunoreceptor tyrosine-based
activation motifs (ITAMs) suggesting the involvement of a recep-
tor in the synergy between heme and PAMPs (Underhill and
Goodridge, 2007; Figure 3). On the other hand, Syk is also acti-
vated independently of cell surface receptors by disturbances in
lipid rafts domains (Ng et al., 2008; Figure 3). Because of heme’s
capacity to intercalate cellular membranes we cannot exclude
the possibility that Syk might be activated by the direct con-
tact of heme with cellular membranes. It will be important to
investigate whether heme-induced Syk phosphorylation requires
a receptor.
THE NLRP3 INFLAMMASOME
WhileTNFand IL-6 aremainly regulated at the transcriptional and
translational levels, cytokines such as IL-1β and IL-18 requires two
steps to be produced. These cytokines are expressed as zymogens,
pro-IL-1β and pro-IL-18, which are regulated by the synthesis
of their mRNA by TLRs. However, IL-1β and IL-18 maturation
requires cleavage of their zymogens by caspase-1 (Cerretti et al.,
1992; Thornberry et al., 1992), which is activated independently
of TLR signaling. The cleavage of these pro-forms is necessary
for their biological effects. Caspase-1 is activated by a multienzy-
matic platform called the inﬂammasome, which is composed of
NLRs (NOD-like receptors),ASC (apoptosis-associated speck-like
protein), and caspase-1 (Martinon et al., 2002; Wen et al., 2013).
NLRP3 (nucleotide-binding domain, leucine rich family, pyrin
containing 3 gene) is the best characterized inﬂammasome recep-
tor and is activated by several DAMPs such as ATP, Hz, amyloid β,
uric acid crystals, and cholesterol crystals (Mariathasan et al., 2006;
Martinon et al., 2006; Halle et al., 2008; Shio et al., 2009; Duewell
et al., 2010;mechanisms reviewed inLatz et al., 2013). Threemech-
anisms are involved in the NLRP3 inﬂammasome activation: K+
efﬂux (Petrilli et al., 2007; Muñoz-Planillo et al., 2013), lysosome
damage (Hornung et al., 2008), and mitochondrial dysfunctions
that lead to mROS generation (Zhou et al., 2011) and the release
of cardiolipin (Iyer et al., 2013) and mitochondrial DNA (Shimada
et al., 2012).
In this context, we found that heme induces IL-1β produc-
tion by activated LPS-primed macrophages promoting NLRP3-
dependent processing of IL-1β (unpublished). Although heme is
capable of activating TLR4, it does not induce IL-1β expression
(Figueiredo et al., 2007). Heme (Fe-PPIX), but not its analogs,
porphyrin rings without Fe (PPIX) or with metal substitutions
(Pd-PPIX and Sn-PPIX), induces IL-1β processing and release
(unpublished). The activation of NLRP3 by heme required K+
efﬂux, Syk phosphorylation, mROS, and NOX2. On the other
hand, the mechanism was independent of ATP release and lyso-
somal damage (unpublished). Our results are in sharp contrast
with a recent published report that describes the ability of heme to
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FIGURE 3 | Heme activates Syk and amplifies cytokine production
induced by PAMPs. Heme induces Syk phosphorylation in macrophages. The
Syk pathway is essential for heme-induced ROS production. Heme-induced
ROS generation increases MAPKs and NFκB activation and consequently,
cytokine production. Heme ampliﬁes cytokines induced by cell surface
receptors (TLR2, TLR4, TLR5), endosome receptors (TLR3, TLR9), and
cytosolic receptors (NOD1 and NOD2). Moreover, heme ampliﬁes MyD88-
(TNF and IL-6) andTRIF-dependent (IP-10) cytokines. The mechanism by which
heme triggers Syk activation is not known. However, there are two
possibilities. Heme could trigger Syk activation through an unknown surface
receptor or through interaction with lipid rafts. The source of ROS controlled
by Syk is not known but because PKC, NOX, and mitochondria inhibitors
blocks the synergism between heme and PAMPs it is possible to consider
that Syk controls ROS generation by NOX and mitochondria. Although NOX2
is the principal NADPH oxidase complex in phagocytes we cannot exclude
the possibility that other NOX might be involved.
activate the NLRP3 inﬂammasome (Li et al., 2014). (1) Heme and
PPIX caused the maturation of IL-1β in the absence of serum (Li
et al., 2014). In our experimental conditions, heme did not acti-
vate the inﬂammasome in the absence of serum (unpublished).
This same result was previously published (Dostert et al., 2009).
Interestingly, the synergism of heme with PAMPs regarding the
production of TNF and IL-6 is also dependent on serum (Fernan-
dez et al., 2010; Lin et al., 2010). The reason why heme requires
serum to induce part of its inﬂammatory effects needs further
investigation. (2) Heme and PPIX primed the macrophages and
induced IL-1β mRNA expression (Li et al., 2014). It is possi-
ble that the procedure to elicit peritoneal macrophages used in
their study primed the cells for subsequent inﬂammasome acti-
vation. We observed that PPIX did not induce pro-IL-1β or
inﬂammasome activation, suggesting that the iron in the por-
phyrin ring is essential for the effect of heme (unpublished).
(3) Heme-induced IL-1β secretion depended on P2X receptors
(Li et al., 2014). This observation suggests that ATP release is
involved. In fact, ATP release from necrotic cells activates NLRP3
(Iyer et al., 2009). Importantly, their experimental procedure was
made without serum. This could have increased the cell death of
macrophages stimulated with heme and the subsequent released
of ATP. Differently from their results, we demonstrated that heme
induced similar amounts of IL-1β in WT and P2X7-deﬁcient
macrophages (unpublished). Moreover, the use of oxidized ATP
(ATP antagonist) and apyrase (degrades ATP) corroborate that
heme-induced inﬂammasome activation is independent of ATP
(unpublished).
One of the mechanisms responsible for the NLRP3 acti-
vation involves the phagocytosis of crystal structures, subse-
quent lysosome damage and cathepsin B release to the cytosol
(Hornung et al., 2008). In fact, phagocytosis and cathepsin
B inhibition blocks the inﬂammasome activation induced by
crystals, including Hz (Shio et al., 2009). Like heme, Hz also
depends on ROS generation and Syk phosphorylation to acti-
vate NLRP3 (Shio et al., 2009). Heme, on the other hand,
does not require phagocytosis or lysosome damage to induce
IL-1β secretion (unpublished). Thus, heme activates the NLRP3
inﬂammasome with a distinct mechanism compared to ATP
and Hz.
www.frontiersin.org May 2014 | Volume 5 | Article 115 | 9
Dutra and Bozza Heme on innate immunity and inﬂammation
In vivo, heme injection induced IL-1β production and caspase-
1-dependent neutrophil migration in mice peritoneum (unpub-
lished). Moreover, Caspase-1−/− mice were resistant to mortality
induced by hemolysis. On the other hand, heme can be used
to prevent inﬂammation through the induction of HO-1. In
fact, preventive induction of HO-1 induced by heme inhibits
the NLRP3 inﬂammasome activation in the liver (Kim and Lee,
2013) and the lung (Luo et al., 2014) in different pathological
conditions.
POSSIBLE ROLES OF HEME-INDUCED INNATE IMMUNE
RECEPTOR ACTIVATION ON PATHOGENESIS
SICKLE CELL DISEASE AND β-THALASSEMIA
Pathologies associated with intravascular hemolysis are the most
commonly related to heme inﬂammatory effects. SCD and
β-thalassemia are molecular blood disorders caused by mutations
in genes encoding Hb (Heinle and Read, 1948; Pauling et al., 1949;
Ingram, 1957). In SCD, a single point mutation in the Hb gene
encodes a protein that polymerizes under low-oxygen conditions
causing red blood cells (RBC) deformation (sickle shape; Edel-
stein et al., 1973; Browne et al., 1998). Repeated sickling episodes
decrease RBC elasticity rendering them susceptible to hemoly-
sis (Hebbel, 1991). β-Thalassemia is the result of a mutation in
the β-globin chain gene that impairs the β-globin chain pro-
duction and leads to accumulation of the α-globin which can
aggregate causing hemolysis and erythroid precursor premature
death (Khandros et al., 2012). Chronic episodes of hemolyses
increase the concentrations of Hb and heme which are consid-
ered to be the major responsible for vascular inﬂammation in
these diseases (Muller-Eberhard et al., 1968; Chies andNardi,2001;
Figure 4). In fact, hematin injection in healthy volunteers induces
thrombophlebitis and disturbed homeostasis (Simionatto et al.,
1988). Moreover, polymorphisms in the promoter region of the
Hmox1 gene is associated with decreased rates of hospitalization
of patients with acute chest syndrome (ACS; Bean et al., 2012),
a major life-threatening condition for patients with SCD (Glad-
win and Vichinsky, 2008). Repeated vaso-occlusion episodes are
characteristic of SCD and can lead to tissue damage due to IR
(Kaul and Hebbel, 2000; Figure 4). Heme induces the expres-
sion of adhesion molecules in the vasculature (Wagener et al.,
1997, 2001a; Belcher et al., 2014). The adherence of leukocytes and
reticulocytes to the endothelium causes stasis and painful crisis, a
hallmark of SCDpathogenesis (Belcher et al., 2000). β-thalassemic
patients also experience signs of vascular inﬂammation and vaso-
occlusion due to endothelial adhesion of aggregated thalassemic
erythrocytes and reduced NO bioavailability (Bunyaratvej et al.,
1995; Hovav et al., 1999; Hahalis et al., 2008). In this disease, car-
diac complications seem to be the main cause of mortality (Engle
et al., 1964; Spirito and Maron, 1990).
Transgenic SCD mice present typical signs of multiorgan
pathology and vascular inﬂammation such as oxidative stress,
endothelial activation, and reduced NO bioavailability (Pászty
et al., 1997; Ryan et al., 1997; Belcher et al., 2003). Also,
β-thalassemic mice present the same signs of vasculopathy (Vinchi
et al., 2013). This phenotype is similar to that of Hx−/− mice
during hemolysis or heme overload (Tolosano et al., 1999; Vinchi
et al., 2008). In bothmodels, vascular inﬂammationwas associated
with an increase is serum heme concentration and Hx deple-
tion. This fact is also observed in patients with hemolytic anemia
(Muller-Eberhard et al., 1968; Adisa et al., 2013). Hx administra-
tion protects transgenic SCD mice and β-thalassemic mice from
heme-induced oxidative stress and vascular inﬂammation (Vinchi
et al., 2013). Hx works by chelating and delivering heme to the
liver where it is catabolized by HO-1. In this context, Hx-heme
complex-induced HO-1 protects the liver against heme cyto-
toxic effects (Vinchi et al., 2013). The increased HO-1 expression
reduces vascular inﬂammation, vaso-occlusion and liver dam-
age (Belcher et al., 2000; Vinchi et al., 2008, 2013). While Hx
treatment protects SCD mice with severe respiratory symptoms
from acute lung inﬂammation (ALI; Ghosh et al., 2013) and
SCD mice from stasis (Belcher et al., 2014), Hx also improves
cardiovascular functions in β-thalassemic mice (Vinchi et al.,
2013).
Recent studies demonstrated that heme-induced endothelial
cell activation is at least in part mediated by TLR4 signal-
ing. Heme-induced TLR4 activation in endothelial cells leads
to NF-κB activation, adhesion molecules expression and Weibel–
Palade body degranulation (Belcher et al., 2014), which contains
the VWF and P-selectins, molecules involved in SCD vasculopa-
thy (Matsui et al., 2001; Chen et al., 2011a; Figure 4). Blockade
of adhesion molecules, including VWF and P-selectin, inhibits
heme-induced stasis in SCD mice (Belcher et al., 2014). TLR4 is
also involved in heme-induced ACS. The TLR4 speciﬁc antago-
nist, TAK-242, which inhibits TLR4 signaling by the intracellular
domain, protects transgenic SCD mice from heme-induced stasis
and ACS (Ghosh et al., 2013; Belcher et al., 2014). In fact, Tlr4−/−
mice or TAK-242 administration prevented ALI and respiratory
distress induced by heme (Ghosh et al., 2013). These results sug-
gest that TLR4 could be a new therapeutic target for treating
SCD.
Furthermore, antioxidants proved to be efﬁcient modulators of
vascular functions in hemolytic diseases. In fact, PKC inhibition
and antioxidants also protects transgenic SCD mice from heme-
induced stasis (Belcher et al., 2014). PKC was shown to mediate
heme-inducedROSgeneration inmacrophages by the Sykpathway
and in neutrophils by a signaling pathway characteristic of a GPCR
(Porto et al., 2007; Fernandez et al., 2010). BecauseROSgeneration
induced by heme is TLR4-independent (Figueiredo et al., 2007), it
is possible that another receptor might collaborate with TLR4 to
promote vascular inﬂammation.
Another possible mechanism involved in the pathogenesis of
SCD is the release of NETs by neutrophils (Chen et al., 2014).
NETs are ﬁbers composed of chromatin (DNA and histones) dec-
orated with antimicrobial peptides. In contrast to its functions in
host defense against pathogens, which NET exert by trapping and
killing them, exaggerated NET formation is implicated in a num-
ber of pathologies (reviewed by Zawrotniak and Rapala-Kozik,
2013). In this context, NET formation has been shown to con-
tribute to disseminated intravascular coagulation in the course
of inﬂammatory diseases and therefore to morbidity and mortal-
ity in sepsis (Fuchs et al., 2010; Massberg et al., 2010; von Bruhl
et al., 2012). Thus, this effect could contribute to vaso-occlusion
and ACS in the course of SCD. In fact, patients with SCD pre-
sented NET formation in plasma during steady state conditions,
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FIGURE 4 | Heme induces vascular inflammation in hemolytic
diseases. During intravascular hemolysis the serum proteins responsible
for removing heme get saturated and heme can exert its inﬂammatory
effects. (1) Hemolysis can happen due to ischemia/reperfusion, SCD or
β-thalassemia. While in SCD, Hb polymerization alters erythrocytes
physically, in β-thalassemia the accumulation of α-globin aggregates inside
the erythrocytes. In both cases, the erythrocytes became more
susceptible to hemolysis. Hemolysis increases the concentration of Hb
which, under oxidative stress, releases free heme. (2) Heme activates
neutrophils and endothelial cells, by ROS generation. In both cells, heme
induces the expression of complementary adhesion molecules. In
endothelial cells, heme induces TLR4-dependent degranulation of
Weibel–Palade bodies and P-selectins and VWF release. The VWF is
prothrombotic and can increase the adhesion of erythrocytes to the
endothelium. Heme also induces the expression of the adhesion
molecules ICAM-1, VCAM-1, and E-selectins. Neutrophils stimulated by
heme and TNF releases NETs. (3) These events lead to the adhesion of
neutrophils to endothelial cells. The activated endothelium now expresses
molecules that can interact with surface molecules localized in
erythrocytes. Also, erythrocytes express molecules that can interact with
platelets. Together, these events lead to vaso-occlusion. (4) Depending on
the extension of the vaso-occlusion, some tissues may experience
hypoxia and damage. Vaso-occlusion of the lung microvasculature may
result in the development of the ACS through the infarction of the lung
parenchyma. Heme-induced TLR4 activation in endothelial cells and NETs
release contribute to the ACS.
when compared to healthy individuals (Schimmel et al., 2013).
The amount of NET formation was increased during painful cri-
sis and ACS, and correlated with the length of hospitalization.
Moreover, TNF administration in SCD mice induced NET forma-
tion within the pulmonary microvasculature (Chen et al., 2014).
DNAse I treatment prevented lung inﬂammation and vascular per-
meability induced by TNF in SCD mice. In this study heme was
reported to mediate NET formation in SCD mice. In vitro, TNF-
primedneutrophils releasedNETs after the stimulationwith heme.
Furthermore, Hx treatment prevented TNF-induced NET forma-
tion and hypothermia in SCD mice demonstrating an important
role for heme in the induction of NET formation in this model.
Together, these data suggest that heme-induced NET formation
might contribute to the pathogenesis of SCD (Figure 4).
ATYPICAL UREMIC HEMOLYTIC SYNDROME
Atypical hemolytic uremic syndrome (aHUS) is characterized by
an over activation of the complement alternative pathway (CAP)
due to genetic and acquired abnormalities (Noris and Remuzzi,
2009). The pathogenesis of this disease involves glomerular
endothelial damage, leukocyte activation, thrombotic microan-
giopathy (blood clots in small blood vessels), and mechanical
hemolysis. However, the observed mutations are insufﬁcient to
induce complement abnormal activation requiring a triggering
stimulus for disease manifestation. A broad range of precipi-
tating events is related with aHUS including infections, drugs,
autoimmune conditions, transplants, pregnancy, and metabolic
conditions (reviewed in Loirat and Fremeaux-Bacchi, 2011).
It was suggested that heme derived from hemolysis could act
as a secondary hit capable of amplifying aHUS pathogenesis
(deCiutiis et al., 1978; Mold et al., 1995; Ruiz-Torres et al., 2005;
Pawluczkowycz et al., 2007). In fact, heme activates the CAP
in the serum and on endothelial cells surfaces (Frimat et al.,
2013). This effect is enhanced by mutations associated to CAP
overactivationduring aHUS.Heme-induced exocytosis ofWeibel–
Palade bodies from endothelial cells induces the expression of
P-selectins in the plasma membrane, which are known to bind
the complement C3b protein and trigger CAP activation, and
to release the prothrombotic VWF (Frimat et al., 2013). More-
over, heme induces the release of C5a and C5b9, fragments
of the C5 complement protein known to induce endothelial
cell activation and permeabilization. Thus the combined effect
of heme-induced CAP and TLR4 activation in endothelial cells
(Frimat et al., 2013; Belcher et al., 2014) may act together to induce
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Weibel–Palade body degranulation, contributing to renal damage
in aHUS.
INTRACEREBRAL HEMORRHAGE
Intracerebral hemorrhage is a bleeding into the brain parenchyma.
Although the mass effect of an edema derived from an expanding
hematoma mediates part of the brain injury, there are evidences
pointing inﬂammation and cytotoxic degradation products of
blood as mediators of ICH injury (Xi et al., 2006). While Hx injec-
tion protects brain tissues from rat cerebral IR (Dong et al., 2013),
Hx−/− mice are susceptible to ICH (Chen et al., 2011b) suggest-
ing a role for free heme in this process. In fact, bleeding will result
in hemolysis and free heme release. Depending on experimental
conditions, HO-1 can be deleterious or beneﬁcial in neurodegen-
erative models. Interestingly, in a mouse model of ICH,Hmox−/−
mice present reduced brain damage (Wang and Doré, 2007) sug-
gesting that cerebral cells are prone to the oxidative effects of free
Fe derived from heme catabolism. In fact, the treatment with the
Fe chelator deferoxamine ameliorates brain injury after ICH or
subarachnoid hemorrhage (Gu et al., 2009; Lee et al., 2010; Chen
et al., 2011c).
TLR4 has been involved in brain injury during ICH (Teng
et al., 2009; Sansing et al., 2011; Fang et al., 2013; Wang et al.,
2013). Exogenous heme induces brain injury through TLR4-
induced inﬂammation (Lin et al., 2012). In fact, Tlr4−/− or
anti-TLR4 treatment suppresses heme-induced neuroinﬂamma-
tion, edema, and neurologic deﬁcit. Moreover, heme activates
microglia cells to produce TNF, IL-6, and IL-1β through TLR4 sig-
naling indicating that heme can directly activate brain cells (Lin
et al., 2012). Heme-induced IL-1β production during neuroin-
ﬂammation suggests the involvement of the NLRP3 inﬂamma-
some. In macrophages, heme induces IL-1β secretion via mROS
generation and NLRP3 activation (Li et al., 2014; unpublished
data). Interestingly, NLRP3 knockdown and mROS inhibitors
reduce brain edema and improve neurological functions (Ma et al.,
2014).
ATHEROGENESIS
Atherosclerosis is a chronic inﬂammatory disease characterized
by the formation of plaques in the vessel walls (Libby et al.,
2002). Plaque formation is initiated by lipid accumulation in
subendothelial spaces and metabolic dysfunction in inﬁltrating
monocyte-derived macrophages which contributes to foam cells
development (Moore and Tabas, 2011). Part of these cells die and
release their fat and cholesterol-laden membranes into the inter-
cellular space recruiting more monocytes in a chronic process that
increases the formation of the necrotic core (Guyton and Klemp,
1996; Virmani et al., 2005). The necrotic core rupture can lead to
serious complications. The release of plaque components into the
blood stream form clots that damages the heart muscle and slowly
develop ischemic heart disease (Falk et al., 1995; Arroyo and Lee,
1999). Also, if these clots are big enough they can block blood
ﬂow and induce tissue necrosis. On the other hand, the necrotic
core rupture exposes inﬂammatory components which can bind
platelet cells at the rupture site and induce their accumulation
forming thrombus which can be large enough to produce vessel
lumen narrowing (Virmani et al., 2005).
Low-density lipoprotein is the major lipid involved in plaque
formation. In the inﬂammatory environment, subendothelial
LDL is oxidized and becomes a potent inﬂammatory molecule.
oxLDL activates intraplaque macrophages by the TLR4–TLR6–
CD36 complex engagement leading to the activation of the NFκB
pro-inﬂammatory pathway and facilitating endocytosis (Stew-
art et al., 2010). oxLDL endocytosis leads to the formation of
crystalline substances inside lysosomes causing the destabiliza-
tion of this organelle as well the release of proteases, events
that lead to the NLRP3 inﬂammasome activation (Duewell et al.,
2010). Indeed, TLRs and NLRP3 have been associated with
atherosclerosis development.
Low-density lipoprotein oxidation and its inﬂammatory effects
can be enhanced by the development of new vessels inside
the necrotic core (Virmani et al., 2005). The major stimulus
for this angiogenic process seems to be hypoxia (Bjornheden
et al., 1999; Sluimer et al., 2008). In fact, the plaque atheroma
composition decreases oxygen availability rendering the necrotic
core structure a hypoxic condition. Furthermore, inﬂamma-
tory cells can actively contribute to angiogenesis by secretion
of angiogenic factors, such as vascular endothelial growth fac-
tor (VEGF), ﬁbroblast growth factor 2 (FGF2), and platelet-
derived growth factor BB (PDGFBB) ligands (Cheng et al., 2013).
The new vessels generally arise from vasa vasorum (Kwon
et al., 1998), a network of small blood vessels that supply the
walls of large blood vessels. Plaque new vessels are immature
and present a fragile structure which is prone to leakage and
highly vulnerable to rupture, thus causing intraplaque hem-
orrhage (Kolodgie et al., 2003; Dunmore et al., 2007; Sluimer
et al., 2009). This event is responsible for increased entry of
erythrocytes and inﬂammatory cells inside the necrotic core.
Erythrocytes that enter developing atherosclerosis lesions are
prone to lysis by lipid oxidation products. Erythrocytes lysis
increases the amount of extracellular Hb which in a highly oxida-
tive environment leads to MetHb formation and the release
of free heme. LDL oxidation induced by heme increases the
oxidation of lipids and inﬂammatory stimuli, contributing to
further plaque development (Balla et al., 1991a). In fact, heme-
induced LDL oxidation is highly cytotoxic for endothelial cells
and LDL oxidation seems to be mediated by Fe (Jeney et al.,
2002; Nagy et al., 2010). This group of events, triggered by
plaque hemorrhage, increases plaque vulnerability and conse-
quently raises the risk of thrombus formation and ischemic
heart disease (Michel et al., 2011). Expression of HO-1 pro-
vides protection against several cardiovascular diseases, including
atherosclerosis (reviewed by Wu et al., 2011). Interestingly, a
6-year-old patient with HO-1 deﬁciency experienced a severe
atherosclerotic pathology (Yachie et al., 1999). This patient suf-
fered from persistent intravascular hemolysis, anemia, endothelial
damage, iron deposition, and cellular sensibility to heme cyto-
toxic effects. These observations resemble those of Hmox−/−
mice, thus demonstrating the importance of HO-1 functions
in the maintenance of iron recycling and tissue homeosta-
sis.
After hemolysis, sustained interaction between Hb and ROS
can lead to ferrylhemoglobin (ferrylHb) formation, which is
characterized by an increase in the Fe oxidative state to Fe+4
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(Harel and Kanner, 1988; Patel et al., 1996). ferrylHb undergoes
intermolecular cross-linking of its globin chains forming aggre-
gates, which induces the expression of adhesion molecules
in vascular endothelial cells that support the recruitment of
macrophages into the vessel wall (Silva et al., 2009; Potor et al.,
2013). Similarly to heme, ferrylHb activates endothelial cells
through NFκB activation (Silva et al., 2009). However, the mech-
anism responsible for NFκB activation is different. While TLR4
and ROS mediate heme-induced activation of macrophages and
endothelial cells (Figueiredo et al., 2007; Belcher et al., 2014),
ferrylHb activates endothelial cells independently of TLR4 and
ROS (Silva et al., 2009). Moreover, ferrylHb is unable to induce
cytokine secretion by endothelial cells (Silva et al., 2009), another
difference to heme which induces IL-8 production (Natarajan
et al., 2007). Like MetHb, ferrylHb is unstable and releases free
heme to further increase oxLDL formation (Potor et al., 2013).
Thus, heme and ferrylHb can induce direct effects, such as
endothelial cells activation, and indirect effects, like LDL oxida-
tion to increase atheroma plaque development and atherosclerosis
pathogenesis.
Besides heme pro-inﬂammatory capacity in atherosclerotic
plaque development, it was proposed that heme could mediate
an atheroprotective event. Recently, heme was shown to activate
human monocytes by the induction of activating transcription
factor 1 (ATF-1), coupling the expression of HO-1 and liver X
receptor (LXR)-β to induce a speciﬁc macrophage phenotype
(Boyle et al., 2012). HO-1 is well known for its homeostatic
functions creating an antioxidant and cytoprotective environ-
ment against heme and Fe deleterious effects (Gozzelino et al.,
2010). LXR-β protects against lipid overload by activating a lipid
exportation program regulated by proteins such as LXR-α and
ATP binding cassette transporter A1 (ABCA1), preventing foam
cells formation. This phenotype induced by heme is distinct from
M1, M2, and Mox (reviewed in Moore et al., 2013) and there-
fore was named Mhem. Mhem was described in macrophages
from atheroma plaques of patients with fatal coronary artery dis-
ease (Boyle et al., 2009). In this context, ATF-1 is able to convert
macrophages to an atheroprotective state coordinating Fe and lipid
metabolism.
The Mhem phenotype contrasts with the Fe-loaded M1
macrophages phenotype which presents an enhanced produc-
tion of TNF and hydroxyl radicals, and has the capacity to
induce precocious ﬁbroblast senescence, impairing wound heal-
ing (Sindrilaru et al., 2011). Macrophages with this phenotype
were described in the skin of patients with chronic venous leg
ulcers (CVUs). This disease is caused by chronic venous valve
insufﬁciency that leads to hypertension in the lower-limb veins,
with persistent erythrocyte extravasation. Erythrophagocytosis by
tissue macrophages and release of heme-bound Fe seems to be
the trigger of this pro-inﬂammatory phenotype. It will be inter-
esting to investigate the presence of Mhem in other pathologies
such CVUs to understand the environments and factors involved
in the development of Mhem and its capacity to modulate pro-
inﬂammatory microenvironments also induced by heme and Fe.
Moreover, it will be interesting to characterize the putative involve-
ment of innate immune receptors activated by heme in these
processes.
HEMOLYSIS DUE TO INFECTION
Vascular hemolysis is a relevant factor in some infectious diseases.
The severe pathology observed in malaria and hemorrhagic fevers
is a result of complex events that triggers a vigorous inﬂammatory
response. The systemic inﬂammatory response and the dissemi-
nated intravascular coagulation observed in severe cases of these
diseases are similar to septic shock and are also dependent on
the production of high amounts of inﬂammatory mediators such
as TNF, IL-6, and IL-1β. Heme homeostasis is critically involved
in the development of sepsis and malaria (Pamplona et al., 2007;
Larsen et al., 2010; Gozzelino et al., 2012). In both cases it is possi-
ble to observe high amounts of heme in the circulation (Figure 4).
In malaria, it was demonstrated that heme acts together with high
amounts of ROS to induce the disruption of the blood–brain bar-
rier permitting the migration of inﬂammatory cells, plasmatic
proteins, and Plasmodium antigens, which cause damage to brain
tissues (Pamplona et al., 2007). In the CLP (cecal ligation and
puncture) model of sepsis, heme sensitizes hepatocytes to necrotic
cell death rendering mice more susceptible to sepsis (Larsen et al.,
2010). Moreover, there is a negative correlation between Hx serum
concentration and tissue damage in patients with septic shock.
Therefore, patients with septic shock presenting higher serum
concentrations of Hx develop decreased tissue damage and have
a better survival outcome, suggesting an important role for heme
during sepsis (Larsen et al., 2010). As discussed,Hx inhibits several
pro-inﬂammatory effects induced by heme such as ROS genera-
tion, cell death (Larsen et al., 2010; Gozzelino et al., 2012), and
the synergistic effect (Lin et al., 2010) with PAMPs. HO-1 has a
central role in maintaining tissues homeostasis against heme nox-
ious effects, sinceHmox−/− mice are extremely susceptible to CLP
and cerebral malaria (Pamplona et al., 2007; Larsen et al., 2010).
In both cases, HO-1 maintains tissue homeostasis independently
of parasite burden. Thus, HO-1 confers tolerance against these
infectious diseases. On the other hand, HO-1 induction confers
host resistance, rather than tolerance, to Mycobacterium infection
(Silva-Gomes et al., 2013). Hmox1-/- mice infected with M. avium
presented a susceptible phenotype with an increased pathogen
burden due to impaired protective granuloma formation. HO-
1 deﬁciency induced heme accumulation and macrophage cell
death which contributed to M. avium proliferation. In fact, heme
administration tomacrophages in vitro increasedM. avium prolif-
eration and heme injection in infected mice prevented granuloma
formation. Moreover, Hmox1-/- mice infected with M. tuberculo-
sis died while WT and heterozygous mice (Hmox1+/-) survived.
Thus, HO-1 plays a critical role during Mycobacterium infec-
tion by preventing heme-induced granuloma macrophage death
and bacterial proliferation. Besides its role in tissue tolerance
and bacterial control, HO-1 antioxidant activity might contribute
to intracellular bacterial multiplication. In fact, HO-1 impairs
resistance to Plasmodium infection in the liver (Epiphanio et al.,
2008) and to non-typhoid Salmonella (NTS), a common com-
plication of P. falciparum infection (Cunnington et al., 2012a,b).
In fact, hemolysis triggered by Plasmodium infection causes pre-
mature mobilization of bone-marrow granulocytes with impaired
antioxidant defenses due to HO-1 expression (Cunnington et al.,
2012a,b). This leads to uncontrolled bacterial load and lethal bac-
teremia. Together these observations reinforce the concept that
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heme might be used as a target for adjuvant therapies during
infectious diseases.
FUTURE PERSPECTIVES
The last 10 years of research on heme inﬂammatory properties
brought new insights to understand its functions in hemolytic
and hemorrhagic pathologies. Besides the fact that heme presents
direct cytotoxic properties, it is now clear that heme can acti-
vate speciﬁc receptors and signaling pathways to promote ROS
generation, inﬂammation, and programed cell death. Impor-
tant studies demonstrated that heme-induced TLR4 activation
is involved in the pathogenesis of SCD and ICH. Interestingly,
a speciﬁc inhibitor of TLR4 signaling is very efﬁcient prevent-
ing heme-induced vasculopathy and lung injury in mouse models
of these diseases. Moreover, heme activates the NLRP3 inﬂam-
masome inducing IL-1β processing and secretion. The critical
role of the inﬂammasome in the pathological response follow-
ing lethal hemolysis was unveiled. Moreover, new studies are
helping to understand the beneﬁcial properties of heme scav-
enging proteins such as Hx. In fact, Hx was shown to protect
mice against infectious (malaria and sepsis) and non-infectious
(SCD, β-thalassemia, and cerebral IR) models of diseases. Char-
acterizing the role of cell death pathways induced by heme and
the participation of heme transporters on hemolytic diseases
promises interesting perspectives. Thus, understanding themolec-
ular signaling pathways affected by heme might prove useful
to the identiﬁcation of new options for treating pathological
conditions that course with increased extracellular heme and
inﬂammation.
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